US Stock Market Closed

Dashboard

CEL-SCI Corp. (CVM)

bolt HIT FAIR VALUE

Current

- (-)

After Hours

Rating & Fair Value

Fair Value Premium lock
Institutional Holdings

H

Financial Strength

H

Sustainable Growth

S

Industry Comparison

H

Management & Equity

B

Analyst Opinion

H

Leverage & Liquidity

B

Fundamental Variables

H

Rating Performance

FV Performance

*There is a current rating on the stock that is included in these numbers based on its performance so far

About

CEL-SCI Corp. is a biotechnology company, which engages in the research, development, and manufacture of investigational immunotherapy products for the treatment of cancer and infectious diseases. Its product pipeline includes Multikine and Ligand Epitope Presentation System (LEAPS). Multikine is an investigational immunotherapy for the potential treatment of head and neck cancers. LEAPS is categorized into LEAPS-H1N1-DC, a product candidate for the treatment of pandemic influenza for hospitalized patients; and CEL-2000 and CEL-4000 which are vaccine candidates for the treatment of rheumatoid arthritis. The company was founded by Maximilian de Clara on March 22, 1983 and is headquartered in Vienna, VA.

CEO

Geert R. Kersten

Employees

-

Industry

Oncology Biopharmaceuticals

Sector

Healthcare

Headquarters

Vienna

Exchange

New York Stock Exchange

Summary Stats

Market Cap

216M

Revenue

28.6K

Net Income

-34.1M

EPS

-$0.86

Price-to-Earnings

-5.8

Price-to-Book

3.62

Debt-to-Equity

0.33

News

Analyst Ratings

Price targets projected by 1 analyst

High

$19.00

Average

$19.00

Low

$19.00

Ratings calculated by 1 analyst

Buy

1

Hold

0

Sell

0

Last Dividend

Amount

-

Dividend Date

-

Frequency

-

Dividend Yield

Earnings

Most Recent Earnings

Last Earnings for Q2 2022

Last Earnings

Not Available

Actual

-$0.23 -

Consensus

-

Report Date

Year Ago

-0.28

Year Ago Change %

Up 17%

Actual vs Estimates

XX

xxx

Upcoming Estimates Unavailable

Expected EPS
-

-

Actual EPS
-

--

Competitors

star Favorites